Углеводный обмен и функциональное состояние почек при артериальной гипертонии высокого риска. 
Возможности фармакологической коррекции ренометаболического профиля

1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й выпуск. Сахарный диабет, 2011; приложение к выпуску 3.

2. Аметов A.C. Современные методы терапии сахарного диабета 2 типа. Русский медицинский журнал. 2008; 16 (4): 170−177.

3. Аметов A.C., Карпова Е. В. Ранняя комбинированная терапия при сахарном диабете 2 типа. Сахарный диабет, 2011; 3: 80−83.

4. Аметов A.C., Пакус E.H. Эффективность и безопасность комбинации метформина и ситаглиптина в лечении больных сахарным диабетом 2 типа. Сахарный диабет. 2010; 3: 62−65.

5. Анциферов М. Б., Дорофеева Л. Г. Вилдаглиптин новый препарат из класса ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета 2 типа. Фарматека. 2009; 3: 12−16.

6. Анциферов М. Б., Зилов A.B. Перспективы применения ингибиторов дипептидилпептидазы-4 при сахарном диабете 2 типа: инициация и продолжение терапии. Фарматека. 2010; 16: 12−17.

7. Балаболкин М. И., Клебанова Е. М. Новые возможности в достижении компенсации углеводного обмена при сахарном диабете 2 типа: янувия ингибитор дипептидилпептидазы IV типа. Сахарный диабет. 2008; 3: 43−49.

8. Белоусов Ю. Б., Гуревич К. Г. Клиническая фармакокинетика. Практика дозирования лекарств: Спец. выпуск серии «Рациональная фармакотерапия». М.: Литтерра, 2005. 288 с.

9. Борисов И. А. Хроническая почечная недостаточность. В мире лекарств, 1999; 1: 7−11.

10. Ю. Виллхауэр Э. Вилдаглиптин: первый инновационный ингибитор ДПП-4. Сахарный диабет. 2010; 3: 118−120.

11. Н. Галстян Г. Р. Лечение сахарного диабета 2 типа ингибиторами дипептидилпептидазы-4. Ожирение и метаболизм. 2010; 3: 3−6.

12. Дедов И. И., Шестакова М. В. Сахарный диабет и артериальная гипертензия. М.: Медицинское информационное агентство, 2006. -344 с.

13. Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М.: Универсум Паблишинг, 2000; 240 с.

14. Дедов И. И., Шестакова М. В. Сахарный диабет в пожилом возрасте: диагностика, клиника, лечение. Практическое руководство для врачей. М.2011.

15. Дедов И. И., Шестакова М. В., Аметов A.C. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа». Сахарный диабет, 2011; 1: 95−105.

16. Дедов И. И., Шестакова М. В., Сунцов Ю. И. Сахарный диабет с России: проблемы и решения. М.2008; сЗ-6.

17. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии, 2010; 3: 5−26.

18. Древаль A.B., Мисникова И. В., Барсуков И. А., Пончакова Г. В., Кузнецов A.B. Распространенность сахарного диабета 2 типа и других нарушений углеводного обмена в зависимости от критериев диагностики. Сахарный диабет, 2010; 1: 116−121.

19. Древаль A.B., Мисникова И. В., Триголосова И. В., Тишенина P.C. Влияние метформина на углеводный и липидный обмен у лиц с ранними нарушениями углеводного обмена. Сахарный диабет, 2010; 2: 63−67.

20. Карье С. Б., Лонэ-Ваше В., Козловская Н. Л. и др. Изменения фармакокинетики лекарственных средств у больных с почечной недостаточностью. Терапевтический архив. 2005; 77 (6): 78−82.

21. Кисляк О. А., Мышляева Т. О., Малышева Н. В. Сахарный диабет 2 типа, артериальная гипертензия и риск сердечно-сосудистых осложнений. Сахарный диабет, 2008; 1: 45−49.

22. Клиническая фармакология по Гудману и Гилману. Под ред. Гилмана А. Г. М.: Практика, 2006. 1850 с.

23. Клиническая фармакология. Национальное руководство. Под ред. Белоусова Ю. Б., Кукеса В. Г., Лепахина В. К., Петрова В. И. М.: ГЭОТАР-Медиа, 2009. 976 с.

24. Козловская Л. В., Милованов Ю. С., Фомин В. В. Хроническая болезнь почек у пожилых: особенности диагностики и лечения. Consilium medicum Ukraina, 2009; 10: 4−10.

25. Кутырина М. Н., Лившиц Н. Л. Почки и артериальная гипертония. Клиническая фармакология и терапия, 1995; 4 (2): 46−49.

26. Майоров А. Ю. Инсулинорезистентность в патогенезе сахарного диабета 2 типа. Сахарный диабет, 2011; 1:35−43.

27. Маколкин В. И., Подзолков В. И. Гипертоническая болезнь. М.: Русский врач, 2000; 96 с.

28. Мартынов А. И. Высокий сердечно-сосудистый риск: основные составляющие. XXVI Всероссийская образовательная интернет-сессия для врачей, www.internist.ru.

29. Маслова О. В., Сунцов Ю. И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет, 2011; 3:6−11.

30. Моисеев B.C., Кобалава Ж. Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клиническая фармакология и терапия, 2002; 11(3): 16−18.

31. Мухин Н. А. Снижение скорости клубочковой фильтрацииобщепопуляционный маркер неблагоприятного прогноза. Тер. Архив, 2007; 6: 5−10.

32. Мухин H.A., Тареева И. Е., Шилов Е. М. Принципы диагностики и лечения нефрологических больных в амбулаторных условиях. Тер. Архив, 2002; 5: 24−27.

33. Надлежащая клиническая практика. ГОСТ Р 52 379−2005. М.: Стандартинформ, 2005. 34 с.

34. Павлова М. Г. Новые возможности терапии сахарного диабета 2 типа. Результаты пилотной наблюдательной программы по эффективности и безопаности терапии препаратом Галвус (вилдаглиптин) в Москве и регионах Российской Федерации. Фарматека. 2010; 3: 87−90.

35. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр. Кардиоваск тер профил., 2008; 4 (Приложение).

36. Романцова Т. И. Патогенетическое обоснование и эффективность применения вилдаглиптина у больных сахарным диабетом 2 типа. Ожирение и метаболизм. 2009; 3: 16−26.

37. Руководство по организации системы мониторинга безопасности лекарственных средств (фармаконадзора) в компаниях производителях лекарственных средств или держателях регистрационных удостоверений, утв. Росздравнадзором 05.10.2009.

38. Савельева С. А, Крячкова A.A., Курумова К. О., Шахмалова М. Ш., Кутырина И. М., Шестакова М. В. Ожирение фактор риска поражения почек у больных сахарным диабетом 2 типа. Сахарный диабет, 2010; 2: 45−49.

39. Сунцов Ю. И., Болотская JT.JI., Маслова О. В., Казаков И. В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет, 2011; 1: 15−18.

40. Сунцов Ю. И., Дедов И. И., Кудрякова C.B. Государственный регистр сахарного диабета: эпидемиологическая характеристика инсулиннезависимого сахарного диабета. Сахарный диабет, 1998; 1: 41−44.

41. Тареева И. Е., Кутырина И. М., Николаев Л. Ю. и др. Пути тормажения развития хронической почечной недостаточности. Тер. Архив, 2000; 6: 9−14.

42. Федеральный закон от 12.04.2010 N 61-ФЗ «Об обращении лекарственных средств». Российская газета. 2010; 78.

43. Функциональное состояние почек и прогнозирование сердечнососудистого риска. Российские рекомендации. Разработаны комитетом экспертов Всероссийского научного общества кардиологов и Научным обществом нефрологов России. Москва, 2008.

44. Халимов Ю. Ш. Вилдаглиптин: место в терапии сахарного диабета. Сахарный диабет. 2010; 3: 92−97.

45. Шестакова М. В, Шамхалова М. Ш., Ярек-Мартынова И.Я. и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет, 2011; 1: 81−88.

46. Шестакова М. В. Диабетическая нефропатия: фатальное или предотвратимое осложнение? Русский медицинский журнал: независимое издание для практикующих врачей, 2001; 9: 1095−1096.

47. Шестакова М. В. Роль аналога человеческого глюкагоноподобного пептида-1 в терапии сахарного диабета 2 типа. Сахарный диабет. 2010; 3: 106−110.

48. Шестакова М. В., Викулова O.K. Современные возможности фармакотерапии сахарного диабета 2 типа при помощиглюкагоноподобного пептида-1 (ГПП-1). Сахарный диабет. 2007; 1: 1016.

49. Шестакова М. В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. М.: МИА, 2009.

50. Ярек-Мартынова И.Р., Шамхалова М. Ш. Органопротективные эффекты блокаторов рецепторов ангиотензина II у больных сахарным диабетом 2 типа. Сахарный диабет, 2010; 2: 58−61.

51. Abrahamian Н, Francesconi М, Loiskandl A et al. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther, 2004; 6: 31−37.

52. Abuissa H., Jones P., Marso S., O’Keefe J. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol, 2005; 46:821−826.

53. Adamczak M, Rzepka E, Chudek J, Wicek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 2005; 62:114−118.

54. Adamczak M, Szotowska M, Chudek J et al. Plasma adiponectin concentration in patients after successful kidney transplantation a single centre, observational study. Clinical Nephrology. 2007; 67 (6): 381−390.

55. Adamczak M, Wiecek A, Funahashi T et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens, 2003; 16: 72−75.

56. Ahren B, Foley JE, Ferrannini E et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin therapy. Diabetes Care. 2010; 33(4): 730−732.

57. A1-Ahmad A., Rand WM, Manjunath G. et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol, 2001; 38: 955−962.

58. American Diabetes Association. Standards of Medical Care in Diabetes— 2010. Diabetes Care 2010; 33: 11−61.

59. Anavekar N., McMurray J., Velazquez E., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med, 2004; 51: 1285−1295.

60. Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol, 2005; 102: 173−178.

61. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci, 2006; 28: 96−108.

62. Astor B., Hallan S., Miller E., et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol, 2008; 167: 1226−1234.

63. Atkinson AJ Jr, Huang SM Nephropharmacology: drugs and the kidney. Clin Pharmacol Ther. 2009; 86 (5): 453−456.

64. Atkinson AJ Jr, Umans JG Pharmacokinetic studies in hemodialysis patients. Clin Pharmacol Ther. 2009; 86 (5): 548−552.

65. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc, 2004; 96 (11): 1445−1454.

66. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004; 27:547−52.

67. Banerjee M, Younis N, Soran H Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother. 2009; 10 (16): 2745−2757.

68. Bangalore S., Parkar S, Grossman E, Messerli FH. A Meta-Analysis of 94,492 Patients With Hypertension Treated With Beta Blockers to Determine the Risk of New-Onset Diabetes Mellitus. Am J Cardiol 2007;100:1254 -1262.

69. Barlocco D LAF-237 (Novartis). Curr Opin Investig Drugs. 2004; 5 (10): 1094−1100.

70. Bauer L Creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with kidney dysfunction. Pharmacotherapy. 2005; 25:1286−1287.

71. Becker B, Kronenberg F, Kielstein J et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16:1091−1098.

72. Bell DS, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract, 2001; 7: 135 138.

73. Bellone M, Iezzi G, Rovere P et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol, 1997; 159: 5391−5399.

74. Berg A, Combs T, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 2001; 7: 947−953.

75. Berg AH, Scherer РЕ. Adipose tissue, inflammation, and cardiovascular disease. Circ Res, 2005; 96: 939 -949.

76. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens, 1998; 16 (9): 1325−33.

77. Bigazzi R., Bianchi S., Nenci R, et al. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens, 1995; 9: 827−833.

78. Birkenhager WH, Schalekamp MADH. Renal hemodynamics and renal function. In Control Mechanisms in Essential Hypertension. Amsterdam: Elsevier, 1976; 43−63.

79. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on HbAlc, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab, 2006; 8: 436−447.

80. Bluher M, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care, 2007; 30:280−5.

81. Borlheiry AL, Malerbi DA, Franco LJ: The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 17: 1269−1272, 2002.

82. Boyle PJ et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther, 2002; 24: 378−396.

83. Brancati F., Whelton P., Randall В., et al. Risk of end-stage renal disease in diabetes mellitis: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA, 1997; 278: 2069;2074.

84. Braunwald E, Domanski M., Fowler S., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 2004; 351: 2058;2068.

85. Brenner B. Hemodinamically mediated glomerular injury and progressive nature of kidney desease. Kidney Int, 1983; 23: 647−55.

86. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int, 1996; 49: 1774−1777.

87. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl, 1997; 63:124−127.

88. Butler AE, Janson J, Bonner-Weir S et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 2003; 52: 102 110.

89. Caramori M., Fioretto P., Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes, 2003; 52:1036−1040.

90. Cavaghan M, Ehrmann D, Polonsky K. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest, 2000; 106 (3): 329−333.

91. Cederberg H, Saukkonen T, Laakso M, et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. Diabetes Care 2010; 33: 207 783.

92. Cefalu WT, Bell-Farrow A, Wang ZQ, McBride, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abnormal fat composition in NIDDM. Drug Dev Res, 1998; 44: 1−7.

93. Cerasola G, Cottone S, Dignoto G et al. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens, 1989; 7(suppl 6): 332−333.

94. Ceriello A, Quagliaro L, Piconi L et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion moleculesand oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 2004; 53: 701−710.

95. Charriere G, Cousin B, Arnaud E et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem, 2003; 278: 9850−9855.

96. Chen J., Muntner P., Hamm L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med, 2004; 140: 167−174.

97. Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32: 2027;32.

98. Chiasson JL, Josse Rg, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 2072;2077, 2002.

99. Christensen DL, Witte DR, Kaduka L, et al. Moving to an AlC-based diagnosis of diabetes has a different impact on prevalence in different ethnic grpups. Diabetes Care 2010; 33: 580−82.

100. Christensfson AG, Grubb AO, Nilsson JA et al. Serum cystatin C advantageous pompared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med, 2004; 256:510−518.

101. Chudek J, Adamczak M, Karkoszka H et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003; 35: 2186−2189.

102. Cirillo M., Lanti M., Menotti A., et ah Definition of kidney dysfunction as a cardiovascular risk factor: Use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med, 2008; 168: 617 624.

103. Cnop M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003; 46:459−69.

104. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31−41.

105. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis, 2000; 36: 29 -34.

106. Combs T, Berg A, Obici S, Scherer P, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest, 2001; 108: 1875−1881.

107. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens, 2004; 17(11 Pt 2): 16−20.

108. Counahan R, Chantler C, Ghazali S et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child, 51: 875−878.

109. Croda-Todd MT, Soto-Montano XJ, Hernandez-Cancino PA, Juarez-Aguilar E. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin. Biochem, 2007; 40:1084−1087.

110. Croxtall JD, Keam SJ Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2008; 68 (16): 2387−2409.

111. Curhan G., Knight E., Rosner B., Hankinson S., Stampfer M. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med, 2004; 164: 1519−1524.

112. Dager WE What are the important drug use errors in dialysis patients? Pharmacokinetic and pharmacodynamic principles. Semin Dial. 2010; 23 (5): 466−469.

113. Dahlof B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 995−1003.

114. Davies MJ. Insulin secretagogues. Curr Med Res Opin, 2002; 18 (Suppl 1): S22−30 125. de Boer I., Katz R., Cao J., et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care, 2009; 32: 18 331 838.

115. DeFronzo RA, Goodman AM & The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New Engl J Med, 1995; 333: 541−549.

116. Del Prato S, Heine R, Keilson L, et al. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care, 2003: 26: 2075;2080.

117. Del Prato S, Marchetto S, Pipitone A, Zanon M, Vigili de Kreutzenberg S, Tiengo A. Metformin and free fatty acid metabolism. Diabetes Metab Rev, 1995; 11: S33-S41.

118. Dettli L Individualization of drug dosage in patients with renal disease. Med. Clin. North Am. 1974; 58: 977−985.

119. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med, 2000; 29: 790−792.

120. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis, 2002; 40: 221−226.

121. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346: 393−403.

122. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care, 2012; 35 (4): 723−30.

123. Diamond J. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int, 1991; 31 (Suppl): 29−34.

124. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int, 1988; 33: 917 924.

125. Docci D, Bilancioni R, Buscaroli et al. Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron, 1990; 56 (4): 364−367.

126. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes, 1999; 48: 738−744.

127. Donath MY, St0rling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med, 2003; 81: 455−470.

128. Droumaguet C, Balkau B, Simon D, et al. Use of HbAlc in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006; 29: 1619−25.

129. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 4 diabetes. Lancet, 2006; 368:1696−1705.

130. Efstathiou SP, Tsioulos DI, Tsiakou AG et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke, 2005; 36: 1915;1919.

131. Eliaschewitz F, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res, 2006; 37: 495−501.

132. Engeli S, Feldpausch M, Gorzelniak K et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003; 52: 942−947.

133. Ericsson K, Lingarde F. Prevention of type 2 (non insulin dependent) diabetes mellitus by diet and physical exercise. Diabetologia, 1991; 34: 891 898.

134. Eriey C, Haefele U, Haune N et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension, 1993;21:810−815.

135. European Best Practice Guidelines for Haemodialysis. Part I. Nephrol Dial Transplant 2002; 17 (Suppl 7): 7−15.

136. European Medicines Agency. Guidance for Industry: pharmacokinetics in patients with impaired renal function study design, data analysis, and impact on dosing and labeling. 2004; http://www.emea.europa.eu/pdfs/human/ewp/2 2502en.pdf.

137. Fanelli CG, Porcellati F, Rossetti P, Bolli GB. Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis, 2006; 16 (Suppl 1): S28-S34.

138. Fasshauer M, Klein J, Neumann S et al. Adiponectin gene expression is inhibired by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett, 2001; 507:142−146.

139. Ferrannini E., Seghieri G., Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol, 1994; 24 (Suppl 3): 61−69.

140. Festa A., D’Agostino R., Howard G., et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int., 2000; 58:1703−1710.

141. Filler G, Bokenkamp A, Hofmann W et al. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem, 2005; 38: 1−8.

142. Filler G, Browne R, Seikaly MG. Glomerular filtration rate as a putative 'surrogate end-point' for renal transplant clinical trials in children. Pediatr Nephrol, 2003; 18: 981−985.

143. Finney H, Bates CJ, Price CP. Plasma cystatin C determinations in a healthy elderly population. Arch Gerontol Geriatr, 1999; 29: 75−94.

144. Fliser D, Ritz E. Does essential hypertension cause progressive renal disease? J Hypertens Suppl, 1998; 16: 13−15.

145. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis, 2001; 37: 79−83.

146. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA, 2000; 283: 16 951 702.

147. Fontana L., Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007; 56:1010−1013.

148. Foster M., Hwang S., Larson M., et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: Association between cardiovascular disease risk factor and clinical outcomes. Arch Intern Med, 2007; 167:1386−1392.

149. Fox C., Larson M., Leip E. Glycemic status and development of kidney disease: The Framingham Health Study. Diabetes Care, 2005; 28: 2436−2440.

150. Fox C., Larson M., Leip E., et al. Predictors of new-onset kidney disease in community-based population. JAMA, 2004; 291: 844−850.

151. Fox C., Muntner P. Trends in diabetes, high cholesterol, and hypertension in chronic kidney disease among U.S. adults: 1988;1994 to 1999;2004. Diabetes Care, 2008; 31:1337−1342.

152. Freed MI et al. Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol, 2002; 90: 947−952.

153. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int, 2003; 63: 1944;1947.

154. Fruebis J, Tsao T, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA, 2001; 98: 2005;2010.

155. Furuhashi M, Ura N, Hishiura K et al. Blockade of renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension, 2003; 42:76−81.

156. Garg A., Kiberd B., Clark W., et al. Albuminuria ad renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int, 2002; 61: 2165−2175.

157. Gerich JE. Control of glycaemia. Baillieres Clin Endocrinol Metab, 1993; 7: 551−586.

158. Gerstein H., Mann J., Yi Q., et al. HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 2001; 286: 421−426.

159. Gerstein H., Pogue J., Mann J. et al. The relationship between dysglycemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 2005; 48: 1749−1755.

160. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305−12.

161. Giaconi S, Levanti C, Fommei E et al. Microalbuminuria and causal and ambulatory blood pressure and monitoring in normotensive and in patients with borderline and mild essential hypertension. Am J Hypertens, 1989; 2: 259−61.

162. Gilardini L, McTernan P, Girola A et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis, 2006; 189: 401−407.

163. Go A, Chertow G, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296−1305.

164. Goke B, Hershon K, Kerr D et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab res. 2008; 40: 892−895.

165. Goldberg RB, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005; 28: 1547−1554.

166. Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res, 2006; 29: 839−847.

167. Grubb A, Lofberg H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc. Natl. Acad. Sci, 1981; 79 (9): 3024−7.

168. Grubb A. Cystatin C — properties and use as diagnostic marker. Adv Clin Chem, 2000; 35: 63−99.

169. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol. 2007; 92:399−404.

170. Gucciardi E, Chi-Tyan Wang S, DeMelo M et al. Characteristics of men and women with diabetes: Observations during patients' initial visit to a diabetes education centre. Can Fam Physician, 2008; 54 (2): 219−227.

171. Guidance for industry. Diabetes Mellitus Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US department of Health and human services FDA, 2008.

172. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and innondiabetic subjects with and without myocardial infarction. N Engl Med, 1998; 339 (4):229−2234.

173. Hall J., Brands M., Henegar J. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci, 1999; 892: 91−107.

174. Hallan S., Astor B., Romundstad S., et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med, 2007; 167: 2490−2496.

175. Hamman RF. Epidemiology of microvascular complications//In: Inernational Textbook of Diabetes Mellitus. Ed. By KGMM Alberti, P. Zimmet, RA DeFronzo. John Wiley&Sons Ltd, 1997; 1.2: 1293−1313.

176. Hanefeld M, Dickinson S, Bouter K, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care, 2000; 23: 202−207.

177. Hanley AJ, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J. Clin. Endocrinol. Metab.2007; 92: 2665−2671.

178. Hannedouche T, Chauveau P, Kalou E et al. Factors effecting progression in advanced chronic renal failure. Clin Nephrol, 1993; 39: 31 220.

179. Hansson L., Lindholm L., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet, 1999; 354: 1751−1756.

180. Hara A, Ohkubo T, Kikuya M et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coathypertension by self-measured blood pressure at home: The Ohasama Study. J Hypertens 2007; 25: 321−327.

181. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006; 29: 1357−1362.

182. Hashimoto H., Kitagawa K., Hougaku H., et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation, 2001; 104: 63−67.

183. He YL, Flannery B, Campestrini J et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin. 2008; 24 (6): 1703−1709.

184. He YL, ?abo R, Campestrini J et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol. 2008; 65 (3): 338 346.

185. He YL, Sabo R, Picard F et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res ppin. 2009; 25(5): 1265−1272.

186. He YL, Serra D, Wang Y et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007; 46 (7): 577−588.

187. He YL, Yamaguchi M, Ito H et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2010; 48 (9): 582−595.

188. Heianza Y, Hara S, Arase Y, et al. HbAlc 5−7-6−4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011; 378: 147−155.

189. Heinemann L, Linkeschowa R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644−649.

190. Helske S, Syvaranta S, Lindstedt KA, et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vase Biol. Abstract, 2006; 26: 17 911 798.

191. Henriksen E., Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol, 2003; 196: 171−179.

192. Herbelin A, Nguyen AT, Zingraff J et al. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int, 1990; 37 (1): 116−125.

193. Herman L, Weiernsperger N. Impaired glucose tolerance and metformin: clinical and mechanistic aspects. Br J Diabetes Vase Dis, 2002; 2: 177−183.

194. Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30: 2453−57.

195. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med, 2010; 4- 363 (19): 1833−1845.

196. Hirose T, Mizuno R, Yoshimoto T. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin secretion by nateglinide in IGT subjects. Endocr J, 2002; 49: 649 652.

197. Hivert MF, et al. Associations of adiponectin, resistin, and tumor necrosis factoralpha with insulin resistance. J. Clin. Endocrinol. Metab. 2008; 93:3165−72.

198. Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant, 2003; 18: 2024;2031.

199. Hoist JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard lecture. Diabetologia, 2005; 49: 253−260.

200. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res, 2007; 74: 11−18.

201. Hornych A, Asmar R. Microalbuminuria and arterial hypertension. Presse Med, 1999; 28 (11): 597−604.

202. Horton E, Foley J, Shen S, Baron M. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2004; 20: 883−889.

203. Hostetter TH, Rennke HG, Brenner BM. The case for intra-renal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med, 1982; 72: 375−380.

204. Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006; 444:860−7.

205. Hotta K, et al. Plasma concentrations of anovel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vase. Biol., 2000; 20:1595−9.

206. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001; 50:1126−1133.

207. Howie AJ. «Benign» essential hypertension and kidney damage: a histopatologist’s view. J Hum Hypertens, 1996; 10: 691−694.

208. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem, 1996; 271: 10 697−10 703.

209. Hu P, Yin Q, Deckert F et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009; 49 (1): 39−49.

210. Hu S, Wang S, Dunning B. Glucose-dependent and glucose-sensitizing insulinotropic effects of nateglinide: comparison to sulphonulureas and repaglinide. Int J Exp Diabetes Res, 2001; 2: 63−72.

211. Huang S.-M, Temple R, Xiao S et al. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin. Pharmacol. Ther. 2009; 86(5): 475−479.

212. Hui X, Lam K, Vanhoutte P, Xu A. Adiponectin and cardiovascular health: an update. British Journal of Pharmacology, 2012; 165: 574−590.

213. Hundal RS, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000; 49: 2063;2069.

214. Ignacy W, Chudek J, Adamczak M et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease a follow-up study. Nephron Clin Pract. 2005;101:18−24.

215. Imai J, Katagiri H, Yamada T et al. Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring), 2006; 14: 1132−1141.

216. International Diabetes Federation. 5th edition of Diabetes Atlas, 2011.

217. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327−34.

218. Irie F., Iso H., Sairenchi T., et al. The relationship of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int, 2006; 69: 1264−1271.

219. Iseki K., Ikemiya Y., Kinjo K., et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int, 2004; 65:1870−1876.

220. Iwashima Y, Horio T, Suzuki Y et al. Adiponectin and renal function, and risk of cardiovascular disease. J Hypertens. 2006; 24 (6): 354.

221. Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an Independent Risk Factor for Hypertension. Hypertension, 2004; 43: 13 181 323.

222. Jacob S., Henriksen E., Fogt D., Dietze G. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism, 1996; 45: 535−541.

223. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc, 2007; 55: 182−188.

224. Janka HU, Plewe G, Riddle MC, Kleibe-Frisch C, Scheweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005; 28: 254−259.

225. Jefferson J., Shankland S., Pichler R. Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int, 2008; 74: 22−36.

226. Jia W., Gao X., Pang C., et al. Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS).

227. Jones GR Estimating renal function for drug dosing decisions. Clin Biochem Rev. 2011; 32 (2): 81−88.

228. Jonkers IJ, Mohrschadt MF, Westendorp RG et al. Severe hypetrigliceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomised controlled trial. Am J Med, 2002; 112: 275−280.

229. Julius S., Kjelden S., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004; 363: 2022;2031.

230. Kacerovsky-Bielesz G, Dressier A, Freunscht R. Long-term glycemic control with insulin glargine in type 2 diabetes. Diabetes Res Clin Pract, 2006; 71: 184−191.

231. Kadowaki T, Yamauchi T Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26: 439−451.

232. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest, 2006; 116 :1784−1792.

233. Kahn SE, et al & ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med, 2006; 355: 2427−2443.

234. Kamal AD, Bain SC. Insulin Glulisine: efficacy and safety compared with other rapid-acting insulin analogues. Expert Opin Drug Saf, 2007; 6: 57.

235. Kambham N., Markowitz G., Valeri A., et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int, 2001; 59: 1498−1509.

236. Kappes A, Loffler G. Influences of ionomycin, dibutyrylcycloAMPand tumour necrosis factor-alpha on intracellular amount and secretion of apMl in differentiating primary human preadipocytes. Horm Metab Res, 2000; 32:548−554.

237. Katz A, Nambi S, Mather K, Baron A, Follmann D, Sullivan G, Quon M. Quantitative insulin sensitivity check index: a simple. Accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab, 2000; 85: 2402−2410.

238. Kazumi T, Kawaguchi A, Sakai K et ah Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 2002; 25: 971−976.

239. Keating GM Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010; 70 (16): 2089;2112.

240. Keller C, Katz R, Cushman M et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrology. 2008; 9: 9.

241. Keller CR, Odden MC, Fried LF et al. Kidney function and markers of inflammation in elderly persons without kidney disease: The Health, Aging and Body Composition Study. Kidney Int. 2007; 71(3): 239−44.

242. Kern P., Panganathan S, Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab, 2001; 280: 745−751.

243. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab, 2004; 89: 2548−2556.

244. Kim S, Cho K, Park H. Relationship between plasma adiponectin levels and the metabolic syndrome among Korean people. Endocr J, 2006; 53: 247−254.

245. Kitahara Y, Miura K, Kajioka T, Mine T. Suppressive effect of nateglinide on high fat diet-induced hepatic accumulation of triglicerides iniL.

246. Goto-Kakizaki rats. (Abstract and poster 959-P) 65 Annual Scientific Session of the American Diabetes Association, San Diego, 10−14 June, 2005.

247. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disaese in men. N Engl J Med, 1996; 334 (1): 13−18.

248. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med, 1994; 330: 877- 884.

249. KloverPJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology, 2005; 146: 3417−3427.

250. Knobler H, Benderly M, Boyko V et al. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J of Endocrinology, 2006; 154: 87−92.

251. Knowler W.C. et al. Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346 (6): 393−403.

252. Kondo H, Shimomura I, Matsukawa Y et al. Association of adiponectin mutation, with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 2002; 51:2325−2328.

253. Koopman R., Mainous A., Liszka H., et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med., 2006; 4: 427−432.

254. Kopp HP, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler. Thromb. Vase. Biol., 2003; 23: 1042−1047.

255. Kramer C., Leitao C., Pinto L., et al. Clinical and laboratory profile of the patients with type 2 diabetes mellitus with low glomerular filtration rate and normoalbuminuria. Diabetes Care, 2007; 30: 1998;2000.

256. Kramer H., Nguyen Q., Curhan G. et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA, 2003; 289: 3273−3277.

257. Kurtz T. New treatment strategies for hypertension and insulin resistance. Am J Med, 2006; 119 (Suppl 1): 24−30.

258. Lalonde RL, Wagner JA Drug development perspective on pharmacokinetics studies of new drugs in patients with renal impairment. Clin Pharmocol Ther. 2009; 86 (5): 557−561.

259. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 2006; 55:249−59.

260. Larsson A, Helmersson J, Hansson LO, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest., 2005; 65: 301−305.

261. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem, 2002; 48- 699−707.

262. Leclercq-Meyer V, Ladriere L, Fuhlendorff J, Malaisse W. Stimulation of insulin and somatostatin release by two meglitinide analogs. Endocrine, 1997; 7: 311−317.

263. Lee C, Lee C, Su Y et al. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs. 2004; 27: 835−841.

264. Lehtovirta M, Fosen B, Gullstom M et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Med, 2001; 18: 578−583.

265. Leiter L, Fitchett D, Gilbert R et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). The Canadian journal of cardiology, 2011; 27 (2): 124−131.

266. Leoncini G, Ratto E, Viazzi F et al. Global risk stratification in primary hypertension: the role of the kidney. Journal of Hypertension, 2008; 26 (3): 427−432.

267. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999; 130: 461- 470.

268. Levey AS, Greene T, Kusek JW, et al. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol, 2000; 11:155A.

269. Levy J, Matthews D, Hermans M. Correct Homeostasis Model Assessment (HOMA) Evaluation uses the computer program. Diabetes Care, 1998; 21:2191−2192.

270. Li C, Pan C, Lu J, Zhu Y, Wang J, Deng X. Effects of metformin on patients with impaired glucose tolerance. Diabet Med, 1999; 16 (6): 477−481.

271. Lihn AS, Ostergard T, Nyholm B et al. Adiponectin mRNA expression in subcutaneous adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiology. Endocrinology and Metabolism, 2003; 284: 443−448.

272. Lilly M, Godwin M. Treating prediabetes with metformin. Systematic review and meta-analysis. Can Fam Physician, 2009; 55: 363−369.

273. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol, 2003; 14: 2573−2580.

274. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 2002; 360:57- 58.

275. Lindstrom J., Louheranta A., Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003; 26: 3230−3236.

276. Lithell H., Hansson L., Skoog I., et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens, 2003; 21: 875−886.

277. Ljungman S. Microalbuminuria in essential hypertension. Am J Hypertens, 1990; 3: 956−60.

278. Lupi R, Del Guerra S, Fierabracci V et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes, 2002; 51 (suppl 1): 134−137.

279. Maclsaac R., Tsalamandris C, Panagiotopoulos S., et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, 2004; 27: 195−200.

280. Maclsaac R., Panagiotopoulos S., McNeil K. et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care, 2006; 29:1560−1566.

281. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apMl (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun, 1996; 221: 286−289.

282. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-lbeta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest, 2002; 110: 851−860.

283. Mallamaci F, Zoccali C, Cuzzola F et al. Adiponectin in essential hypertension. J Nephrol, 2002; 15:507−511.

284. Mandani BH, Lim VS, Mahurkar SD, Katz AI et al. Recovery from prolonged renal failure in patients with accelerated hypertension. N Eng J Med, 1974; 291:1343−1344.

285. Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 2010; 33: 2190−95.

286. Marchlewska A, Stenvinkel P, Lindholm B et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int. 2004; 66: 46−50.

287. Martin MV, Barroso S, Herraez O et al. Cystatin C as a renal function estimator in advanced chronic renal failure stages. Nefrolohia, 2006; 26 (4): 433−438.

288. Massi Benedetti M, Humburg E, Dressier A, Ziemen M. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res, 2003; 35:189−196.

289. Massiera F, Bloch-Faure M, Ceiler D et al. Adipose angiotensinogen is involved in adipose tissue groth and blood pressure regulation. FASEB J, 2001; 15: 2727−2729.

290. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412−419.

291. Mayer G Renal function in the elderly and drug dosing. Gerontology. 2009; 55 (4): 417−421.

292. Mazzone T et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006; 296: 2572−2581.

293. McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother, 2001; 2: 699−713.

294. Meigs JB, Muller DC, Nathan DM, Blake DR, Andreas R. The natural history of progression from normal glucose tolerance to the type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes, 2003; 52 (6): 14 751 484.

295. Mero N, Syvanne M, Taskinen M. Postprandial lipid metabolism in diabetes. Atherosclerosis, 1998; 141 (Suppl 1): 53−55.

296. Mikhail N Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008; 17 (6): 845−853.

297. Miller WG Reporting estimated GFR: a laboratory perspective. Am J Kidney Dis. 2008; 52 (4): 645−648.

298. Mimran A, Ribstein J. Microalbuminuria in essential hypertension. Clin Exper Hypertens, 1993; 15 (6): 1061−1067.

299. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertrigliceridemia in Zucker Fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharm Bulll, 2002; 25: 1412−1416.

300. Mitka M. Hemoglobin Ale poised to become preferred test for diagnosing diabetes. JAMA 2009; 301:1528.

301. Moe S, Drueke T, Cunningham J et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2005; 67: 2089;2100.

302. Mogensen CE, Poulsen PL. Epidemiology of microalbuminuria in diabetes and in the background population. Curr Opin Nephrol Hypertens, 1994; 3:248−256.

303. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Brit Med J, 1982; 285: 685−688.

304. Mohan V, Deepa R, Pradeepa R et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism, 2005; 54: 476−481.

305. Mohan V, Vijayachandrika V, Gokulakrishnan K, et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010; 33: 515−19.

306. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med, 2006; 145:125−134.

307. Moorhead JF, Wheeler DC, Varghese Z. Glomerular structures and lipids in progressive renal disease. Am J Med, 1989; 87. (Suppl 5N): 12−20.

308. Moranville MP, Jennings HR Implications of using modification of diet in renal disease versus Cockcroft-Gault equations for renal dosing adjustments. Am J Health Syst Pharm. 2009; 66 (2): 154−161.

309. Morel Y, Golay A, Pernegert T et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabetic Med, 1999; 16- 650−655.

310. Mori Y, Kuriyama G, Tajima N. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine, 2004; 25: 203−206.

311. Mostafa SA, Khunti K, Srinivasan BT, et al. The potential impact and optimal cut-points of using glycated haemoglobin, Hb Ale, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010; 90:100−08.

312. Motillo S, Filion K, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol, 2010; 56:1113−1132.

313. Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA. The value of aggressive therapy in the hypertensive patients with azotemia. Circulation, 1969; 15: 893−904.

314. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. New Engl J Med, 1970; 283: 109−115.

315. Munar MY, Singh H Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007; 75 (10): 1487−1496.

316. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab, 2008; 294: E15-E26.

317. Muntner P., Coresh J., Smith J. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int., 2000; 58: 293−301.

318. Myrup B., de Maat M., Rossing P, et al. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res, 1996; 81: 485−490.

319. Nakahara C., Kanemoto K., Saito N., et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol, 2001; 55: 365−370.

320. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo), 1996; 120: 803- 812.

321. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30:753−59.

322. National Kidney Foundation. K/DOQI Clinical Practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (Suppl 2): 1−180.

323. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39 (Suppl 1): 1−266.

324. Navaro J., Mora C., Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis, 2003; 42: 53−61.

325. Nenness S, Keam SJ. Vildagliptin. Drugs, 2006; 66:1989;2001.

326. Newman DJ. Cystatin C. Ann Clin Biochem, 2002; 39: 89−104.

327. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007; 30: 228−33.

328. Nielson S, Schmitz A., Rehling M., et al. Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes. Diabetes Care, 1993; 16:1427−1432.

329. Nilsson PM, Engstrom G., Hedblad B. et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vase Biol. 2006; 26: 2758−2762.

330. Ninomiya T., Petrovic V., Galan B., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol, 2009; 20:1813−1821.

331. Ninomiya T., Petrovic V., Verdon C, et al. Proteinuria and stroke: A meta-analysis of cohort studies. Am J Kidney Dis, 2009; 53:417−425.

332. NKF-K/DOKI clinical practice guidelines for chronic kidney diseases: evaluation, classification and stratification // Am. J. Kidney Dis. — 2002. — 39 (suppl. 1). —S17—S31.

333. Nolin T, Naud J, Leblond F et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 2008; 83: 898−903.

334. O’Hare AM, Bertenthal D, Covinsky KE et al. Mortality risk stratification in chronic kidney disease: one size for all ages? J Am Soc Nephrol, 2006; 17: 846−853.

335. Okamoto M, Ohara-Imaizumi M, Eto K et al. Adiponectin stimulates insulin secretion via stimulation of insulin secretory granule. Diabetes 2004, 53 (Suppl 2): A39 (Abstract).

336. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999; 22: 394−98.

337. Olson DE, Rhee MK, Herrick K, et al. Screening for diabetes and prediabetes with proposed Alc-based diagnostic criteria. Diabetes Care 2010; 33: 2184−89.

338. Otsuka F., Sugiyama S., Kojima S. et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006; 48:1155−1162.

339. Pahor M, Shorr RI, Somes GW et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic in the elderly program. Arch Intern Med, 1998; 158:1340−1345.

340. Paisley K., Beaman M., Tooke J., et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int, 2003; 63: 624−633.

341. Pajvani UB, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol. Chem., 2004; 279:12 152−62.

342. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications, 1998; 12:110−119.

343. Pan C-Y, Sinnassamy P, Chung K-D, Kim K-W. LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asin type 2 diabetes patients. Diabetes Res Clin Pract, 2007; 76: 111−118.

344. Pan X, Li G, Hu Y et al. Effects of diet and exersice in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes care, 1997; 20: 537−544.

345. Panichi V., Migliori M., de Pietro S., et al. C reactive protein in patients with chronic renal diseases. Renal Fail, 2001; 23: 551−562.

346. Pannacciulli N., Cantatore F., Minenna A., et al. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med, 2001; 250: 502−507.

347. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduced rate of decline in kidney function in diabetic nephropathy. Lancet, 1983; 1: 1175−1179.

348. Parving HH. Microalbuminuria in essential hypertension. J Hypertens, 1996; 14: 89−94.

349. Patane G, Piro S, Rabuazzo A et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose. Diabetes, 2000; 49: 735−740.

350. Pecoits-Filho R., Heimburger O., Barany P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis, 2003; 41: 1212−1218.

351. Pereira R, Snell-Bergeon J, Erickson C, et al. Adiponectin dysregulation and insulin resistance in type 1 diabetes. Journal of endocrinology and metabolism, 2012: 97 (4): E642.

352. Perera G. Hypertensive vascular disease: description and natural history. J Chronic Dis, 1995; 1: 33−42.

353. Perkovic V., Verdon C., Ninomiya T., et al. The relationship between proteinuria and coronary risk: A systematic review and meta-analysis. PLoS Med, 2008; 5: e207.

354. Petersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest, 1976; 36: 231−237.

355. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargin and insulin detemir. Curr Med Res Opin, 2006; 22: 2613−2619.

356. Pfeffer M, Swedberg K, Granger C, et al. Effects of candersartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003; 362: 759−766.

357. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G et al. Urinary albumin excrecion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol, 2000; 11 (10): 1882−1888.

358. Pischon T, Girman CJ, Hotamisligi GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004; 291:17 301 737.

359. Plantinga L., Crews D., Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol, 2010; 5: 673−682.

360. Pollin TI, Tanner K, O’Connell JR, Ott SH, Damcott CM, Shuldiner AR, McLenithan JC & Mitchel BD. Linkage of plasma adiponectin to 3q27 explained by association with variation in the AMPI gene. Diabetes 2005; 54: 268−274.

361. Porte D, Jr Banting lecture 1990. Beta-cells in type 2 diabetes mellitus. Diabetes, 1991 — 40: 166−180.

362. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res, 2006; 38: 423 428.

363. Pucci L, Triscornia S, Lucchesi D et al. Cystatin. C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem, 2007; 53: 480−488.

364. Rakatzi I, Mueller H, Ritzeler O et al. Adiponectin counteracts cytokine-and fatty acid-induced apoptosis in the pancreatic p-cell line INS-1. Diabetologia, 2004; 47:249−258.

365. Recasens M, Lopes-Bermejo A, Ricart W e al. An inflammation score is better associated with basal than stimulate indexes of insulin resistance. J Clin Endocrinol Metab, 2005; 90: 112−116.

366. Redon J., Morales-Olivas F., Galgo A., et al. Urinary albumin excretion and glomerular filtration rate across the spectrum of glucose abnormalities in essential hypertension. J Am Soc Nephrol, 2006; 17 (3): 236−245.

367. Regalleau V., Lasseur C., Raffaitin C., et al. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. Diabetes Care, 2007; 30: 2034;2039.

368. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int, 1997; 51(1): 2−15.

369. Retnakaran R, Hanley AJ, Raif N et al. Adiponectin and (3-cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia, 2005; 48: 993−1001.

370. Retnakaran R., Cull C., Thorne K., et al. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 2006; 55: 1832−1839.

371. Riddle M, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine of humal NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003; 26: 3080−3086.

372. Rigalleau V, Lasseur C, Perlemoine C et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation? Diabetes Care, 2005; 28: 838−843.

373. Rigalleau V., Lasseur C., Raffaitin C., et al. Glucose control influences glomerular filtration rate and its prediction in diabetic subjects. Diabetes Care, 2006; 29: 1491−1495.

374. Ritz E, Fliser D, Klimm HP. Assessment of cardiovascular risk factors: The role of microalbuminuria. Amsterdam, 1994.

375. Robles N. R., Barroso S., Ruiz-Calero R. Papel de la cistatina C en la valoracion de la funcion renal y su relacion con el riesgo cardiovascular. Hipertension (Madr.), 2007; 24(5): 201−208.

376. Roderick PJ, Atkins RJ, Smeeth L et al. Detecting chronic kidney disease in older peoplewhat are the implications? Age Ageing, 2008; 37(2): 179−86.

377. Rosenstock J, Banarer S, Owens D. Insulin Strategies in type 1 and type 2 diabetes mellitus, chapter 29 in Clinical Diabetes (ed. Fonseca, V). Saunders Elsevier, Philadelphia, PA, 2006; 371−394.

378. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, 2007; 30: 217−223.

379. Rosenstock J, Dailey G, Massi-Benedetti M et all. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005; 28: 950−955.

380. Rosenstock J, Shen S, Gatlin M, Foley J. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care, 2002; 25: 1529−1533.

381. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999; 340: 115−126.

382. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens, 1993; 2 (6): 962−7.

383. Rule AD, Larson TS, Bergstralh EJ et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med, 2004; 141: 929 -937.

384. Ryo M, Nakamura T, Kihara S et al. Adiponctin as a biomarker of the metabolic syndrome. Circ J, 2004; 68: 975−981.

385. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med, 1998; 319 (23): 1500−1506.

386. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrot M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 43 672.

387. Sacks DB: College of American Pathologists Glycohemoglobic Survey 2002. Set GH2-A, CAP2000.

388. Saloranta C, Guitard C, Pecher E et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in prediabetic population. Diabetes Care, 2002; 25- 2141−2146.

389. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab, 2002; 87: 4171−4176.

390. Samouilidou E, Grapsa E Relationship of serum cystatin C with C-reactive protein and apolipoprotein Al in patients on hemodialysis. Ren Fail. 2008; 30 (7): 711−715.

391. Saraheimo M, Forsblom C, Fagerudd J et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care. 2005; 28: 1410−1414.

392. Prevention. Circulation, 2003; 108: 2154−2169.

393. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia, 2008; 51(5): 714−725.

394. Schalkwijk C, Chaturvedi N, Schram M et al. EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab. 2006; 91:129−135.

395. Scheen A. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs, 2004; 64: 2537−2565.

396. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem, 1995; 270: 26 746−26 749.

397. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes, 2006; 55: 1537−1545.

398. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12 216 patients. Diabetes Obes Metab, 2007; 9: 31−38.

399. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics, 1976; 58: 259−263.

400. Selvin E, Steff es MW, Gregg E, et al. Performance of A1C for the classification and prediction of diabetes. Diabetes Care 2011; 34: 84−89.

401. Selvin E, Steff es MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 80 011.

402. Selvin E., Ning Y., Steffes W., et al. Glycated Henoglobin and the Risk of Kidney Disease and Retinopathy in Adults with and without diabetes. Diabetes, 2011; 60: 298−305.

403. Shaibi G, Cruz M, Weigensberg M et al. Adiponectin independently predicts metabolic syndrome in overweight latino youth. J Clin Endocrinol Metab, 2007; 92: 1809−1813.

404. Shaw J, et al. Albuminuria present in 10% of those with prediabetes. Am J Kidney Dis, 2004; 44: 792−798.

405. Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res, 2003; 1:189−200.

406. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide analysis model based on the homeostasis model. Diabetes Res Clin Pract, 2003; 62: 87−94.

407. Shlipak M., Katz R., Kestenbaum B., et al. Rapid decline of kidney function increases cardiovascular risk in elderly. J Am Soc Nephrol, 2009; 20: 2625−2630.

408. Shlipak MG, Fried LF, Stehman-Breen C, Siscovick D, Newman AB. Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. Am J Geriatr Cardiol, 2004; 13: 81−90.

409. Shlipak MG, Katz R., Cushman M. et al. Cystatin C and inflammatory markers in ambulatory elderly. Am J Med. 2005; 118 (12): 1416.

410. Shlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005; 352: 2049;2060.

411. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc, 1996; 44: 751−755.

412. Singh D, Whooley MA, Ix JH et al. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007; 22 (4): 1087−1092.

413. Sit D, Kadiroqlu A, Kayabasi H, Yilmaz M. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther, 2006; 23 (6): 988−998.

414. Sjostrom P, Tidman M, Jones I. Determination of the production rate and nonrenal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest, 2005; 65- 111−24.

415. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A: Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care, 2003; 26:3226−3229.

416. Snijder M, Heine R, Seidell J et al. Association of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. The Hoorn Study. Diabetes Care, 2006; 29: 2498−2503.

417. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003; 361:226−228.

418. Staiger K, Stefan N, Staiger H et al. Adiponectin is functionaly active in human islets but does not affect insulin secretory function or P-cell lipoapoptosis. J Clin Endocrinol Metab, 2005; 90: 6707−6713.

419. Standards of medical care in diabetes 2011. American Diabetes Association. Diabetes Care, 2011; 34 (1): 11−61.

420. Stehouwer C., Smulders Y. Microalbuminuria and risk of cardiovascular disease. Analysis of potential mechanisms. J Am Soc Nephrol, 2006; 17: 2106−2111.

421. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha//J. Biol. Chem.- 1991. 266.-P. 21 839−21 845.

422. Stevens AL, Coresh J, Greene T et al. Assessing kidney functionmeasured and estimated glomerular filtration rate. N Engl J Med. 2006; 354: 2473−2483.

423. Stratton I, Adler A, Neil H et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMI, 2000; 321: 405−412.

424. Stuveling E., Bakker S., Hillege H., et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension, 2004.

425. Stuveling E., Hillege H., Bakker S., et al. C-reactive protein is associated with renal function abnormalities in non-diabetic population. Kid Int, 2003; 63: 654−661.

426. Summerson JH, Bell RA, Konen JC. Racial differences in the prevalence of microalbuminuria in hypertension. Am J Kidney Dis, 1995; 26:577−579.

427. Sun H, Fadiran EO, Jones CD et al. Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet. 1999; 37(1): 41−58.

428. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215−21.

429. Takahashi M, Arita Y, Yamagata Y et al. Genomic structure and mutation in adipose-specific gene, adiponectin. Int J Obes Relat Disord, 2000; 24: 861−868.

430. Tanaka A, Suemaru K et al. A New Approach for Evaluating Renal Function. J Pharmacol Sci, 2007; 105: 1−5.

431. Teno S, Uto Y, Nagashima H et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care, 2000; 23:1401−1406.

432. The DECODE Study Group, on behalf of European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and non cardiovascular diseases? Diabetes Care 26: 688−696, 2003.

433. The Diabetes Prevention Program Research Group. Effects of Withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care, 2003; 26: 977−980.

434. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183−1197,1997.

435. The Navigator Study Group. Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med, 2010; 362:1463−1476.

436. The Navigator Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med, 2010; 362:1477−1490.

437. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012; 367 (4):319−28.

438. Tilg H, Moschen A. Inflammatory mechanisms in the regulation of insulin resistance. Mol med, 2008; 14 (3−4): 222−231.

439. Tonelli J, Li W, Kishore P et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes, 2004; 53:1621−1629.

440. Tracy R., Psaty B., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vase Biol, 1997; 17:2167−2176.

441. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep, 2006; 6: 47−54.

442. Trudeau JD, Dutz JP, Arany E et al. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes, 2000; 49: 1−7.

443. Tsalamandris C., Allen T., Gilbert R., et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes, 1994; 43: 649−655.

444. Tschritter O, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 2003; 52:239−43.

445. Tsigos C., Kyrou I., Chala E., et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism, 1999; 48:1332−1335.

446. Tuomilehto J., Lindstrom J., Eriksson J., et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001; 344 (18): 1343−1350.

447. Turk B. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta, 2000; 1477: 98−107.

448. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998; 352: 854−865.

449. UKPDS Study Group. UKPDS 16. Overview of six years' therapy of type 2 diabetes a progressive disease. Diabetes, 1995; 44:1249−1258.

450. Unwin N, Shaw J, Zimmet P, Alberti KGMM: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708−723, 2002.

451. US Food and Drug Administration. Guidance for industry. Pharmacokinetics in patients with impaired renal function study design, data analysis, and impact on dosing and labeling. March 2010. Clinical pharmacology, revision 1.

452. US Food and Drug Administration. March 2008 FDA Pharmaceutical science and clinical pharmacology advisory committee. 2008;http.7/www.fda.gov/ohrms/dockets/ac/cder08.html#PharmScience.

453. Vassalotti J., Chen S., Collins A. Screening populations at increased risk of CKD: The kidney early evaluation program (KEEP) and the public health problem. Am J Kidney Dis, 2009; 53 (Suppl 3): 107−114.

454. Vigushin D., Pepys M., Hawkins P. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in heakth and disease. J Clin Invest, 1993; 91: 1351−1357.

455. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs, 2007; 16: 231−237.

456. Visser M., Bouter L., McQuillan G., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA, 1999; 282: 2131−2135.

457. Volanakis J. Human C-reactive protein: Expression, structure, and function. Mol Immunol, 2001; 38: 189−197.

458. Volhard F, Fahr T. Die brightshche neirenkrankheit. Berlin: Springer,.

459. Waki H, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol. Chem., 2003; 278:40 352−63.

460. Wallace T, Levy J, Matthews D. Use and abuse of HOMA modeling. Diabets Care 2004; 27:1487−1495.

461. Wang J, Li H, Franco O et al. Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity, 2008; 16: 172−178.

462. Wang JG, Staessen JA, Fagard RH et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension, 2001; 37:1069−74.

463. Wang W, Lee ET, Howard BV, et al. Fasting plasma glucose and hemoglobin Ale in identifying and predicting diabetes: the Strong Heart Study. Diabetes Care 2011; 34: 363−68.

464. Wang Y, et al. Posttranslational modifications on the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high-molecular-weight oligomeric complex. J Biol. Chem., 2006; 281:16 391−400.

465. Wargo K, Eiland E, Hamm W et al. Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments. Ann. Pharmacother. 2006; 40: 1248−1253.

466. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Estimation of glomerular filtration rate in the elderly: a comparison ofcreatinine-based formulae with serum cystatin C. J Intern Med, 2004; 256: 70−78.

467. Wayner DM, Burton GW, Ingold KU et al. The relative contributions of vitamin E, urate, ascorbate and proteins to the total perxyl-trapping antioxidant activity of human blood plasma. Boichem Biophys Acta, 1987; 924: 408−419.

468. Weaver J, Robertson D, Atkin S, on behalf of The Nateglinide Glycaemic Control Investigators. Nateglinide alone or with metformin safely improves glycarmia to target in patients up to an age of 84. Diabetes Obes Metab, 2004; 6: 344−352.

469. Weiner DE, Tabatabai S, Tighiouart H et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis, 2006; 48: 392−401.

470. Weisinger J., Kempson R., Eldridge L., Swenson R. The nephrotic syndrome: A complication of massive obesity. Ann Intern Med, 1974; 81: 440−447.

471. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest., 2005; 115:1111−1119.

472. Westhuyzen J., Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci, 2000; 30: 133−143.

473. Weyer C, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86:1930;5.

474. White JR, Campbell RK, Hirsh IB. Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad Med, 2003; 113: 30−36.

475. Wiecek A, Adamczak M, Chudek J Adiponectin an adipokine with unique metabolic properties. Nephrol Dial Transplant. 2007; 22: 981−988.

476. Winzell MS, Nogueiras R, Dieguez C, Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Boichem Biophys Res Common, 2004; 321:154−160.

477. Wisse B. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol, 2004; 15: 2792−2800.

478. Wolowich W, Raymo L, Rodriguez J Problems with the use of the modified diet in renal disease formula to estimate renal function. Pharmacotherapy. 2005; 25: 1283−1284.

479. Wong VS, Brubaker PL. From cradle to grave: pancreatic beta-cell mass and glucagon-like peptide-1. Minerva Endocrinol, 2006; 31: 107−124.

480. Would Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of the WHO Consultation. Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999.

481. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med, 2002; 137: 563−570.

482. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T: Adiponectin, an adipocytederived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin EndocrinolMetab 2004; 89:87−90.

483. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 2002; 8: 1288−1295.

484. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem, 2003; 278: 2461−2468.

485. Yamauchi T, Nio Y, Maki T et al. Targeted disruption of AdipoRl and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med, 2007; 13: 332−339.

486. Yamauchi T., Kamon J., Ito Y. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762−769.

487. Yasuno S et al. Is Pulse Pressure a Predictor of New-Onset Diabetes in High-Risk Hypertensive Patients? A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33:1122−1127.

488. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen R, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia, 2006; 49: 442−451.

489. Yokoyama H., Kanno S., Takahashi S., et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol, 2009; 4: 1432−1440.

490. Yokoyama H., Sone H., Oishi M., et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant, 2009; 24:1212−1219.

491. Young DS. Effects of Drugs on Clinical Laboratory Tests. 3rd ed. Washington, DC. — American Association for Clinical Chemistry Press. -1990.

492. Yusuf S., Sleight P., Pogue J., et al. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342:145−153.

493. Zhang L., Zhang P., Wang F., et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis, 2008; 51: 373−384.

494. Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33: 1665−73.

495. Zhang Y, Zhang L, Abraham S et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin. Pharmocol.Ther. 2009; 85: 305−311.

496. Zhou G et al. aRole of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108: 1167−1174.

497. Zimmerman BR, Sulfonylureas. Endocrinol Metab Clin North Am, 1997; 26: 511−522.

498. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13:134−141.

499. Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int, 1992; 42: 452−458.